InvestorsHub Logo
Followers 138
Posts 22975
Boards Moderated 0
Alias Born 04/08/2004

Re: None

Sunday, 06/19/2022 12:10:33 AM

Sunday, June 19, 2022 12:10:33 AM

Post# of 459843
Wednesday 22 June 2022, Christopher Missling
Company: Anavex Life Sciences


Job title: President & Chief Executive Officer

Seminars:
Characterizing Rare Disease Biology in Clinical Studies to Observe Drug Effects in Patient Sub-Populations 11:00 am

Understanding the relevance of Whole Exome Sequencing (WES) and mRNA-seq analyses Using unsupervised computerized AI analysis to assess large data Correlating genomic analysis with extensive clinical data outcomes and endpoint scales

Details:

Understanding the relevance of Whole Exome Sequencing (WES) and mRNA-seq analyses

Using unsupervised computerized AI analysis to assess large data

Correlating genomic analysis with extensive clinical data outcomes and endpoint scales

Day: Day One

https://rare-genetic-neurodegenerative-development.com/speaker/christopher-missling-2/

Good luck and GOD bless,
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News